MBX Biosciences is trading at $65.03 (5.3% up) today, extending a strong upward trend since late June following favorable coverage of study data in chronic hypoparathyroidism.
- The company recently highlighted robust Phase 2 results for canvuparatide and emphasized its current financial strength.
- Shares continue to react positively as investors reassess the company's clinical pipeline and its opportunity within the rare endocrine disease market.